EDAP TMS S.A. Retains Halliburton Investor Relations as Counsel
25 Enero 2005 - 5:00AM
PR Newswire (US)
EDAP TMS S.A. Retains Halliburton Investor Relations as Counsel
Company to Begin Enhanced Shareholder Communications and Outreach
Program LYON, France, Jan. 25 /PRNewswire-FirstCall/ -- EDAP TMS
S.A. (NASDAQ:EDAP), today announced it has retained Halliburton
Investor Relations to assist the company in its efforts to
communicate with the investment community. Hugues de Bantel, Chief
Executive Officer of EDAP TMS, commented: "We are pleased to move
forward in sharing our corporate strategy with the professional
investment community. In the last year, we have made substantial
strides in our operational success, including an objective of
division profitability and significant sales growth. Our new
partnership with Halliburton Investor Relations will enable us to
more fully communicate our success and plans for the future to a
broader audience. Halliburton Investor Relations has a proven track
record of successful strategic investor communications programs for
publicly traded companies." Alan Halliburton, President of
Halliburton Investor Relations, said: "EDAP is a successful,
growing and innovative company but has remained undiscovered by the
investment community. We believe the company's success in its
product lines and future growth opportunities, especially the High
Intensity Focused Ultrasound (HIFU) treatment of prostate cancer
where EDAP is a clear market leader, make it a prime candidate for
our strategic investor relations program. With management, we will
work to broaden EDAP's corporate visibility and help achieve
improved liquidity as well as a proper valuation of the company's
stock within the marketplace." Based in Dallas, Texas, Halliburton
Investor Relations was formed in 1990 to provide a superior caliber
of investor relations representation to publicly traded companies.
The firm develops strategic communications programs designed to
cultivate highly targeted relationships in the financial community
and improve the visibility of successful public companies to
investors. For more information, visit the company's Web site at
http://www.halliburtonir.com/. EDAP TMS S.A. develops and markets
Ablatherm, the most advanced and clinically proven choice for High
Intensity Focused Ultrasound (HIFU) treatment of localized prostate
cancer. HIFU treatment is shown to be a minimally invasive and
effective treatment option with a low occurrence of side effects.
The company is also developing this technology for the treatment of
certain other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more
information on the Company, contact the Investor Relations Dept by
phone at +33 (0)4 78 26 40 46 or see the Company's Web site at:
http://www.edap-tms.com/. This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. Web sites:
http://www.edap-tms.com http://www.halliburtonir.com DATASOURCE:
EDAP TMS S.A. CONTACT: EDAP TMS S.A. -- Hugues de Bantel - Philippe
Chauveau, Blandine Confort, +33-4-78-26-40-46, or Halliburton
Investor Relations -- Matt Kreps - Geralyn DeBusk, +1-972-458-8000
Copyright
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024